![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial
Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial
![pfizerlogo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images/pfizerlogo.gif?t=1576044507&width=430)
July 18, 2016
Pfizer has unveiled positive results from a Phase 3 trial evaluating Sutent as adjuvant therapy in patients at high risk of recurrent renal cell carcinoma after surgery.
The tyrosine kinase inhibitor reached its primary endpoint of prolonging disease-free survival in the adjuvant setting compared to placebo.
The treatment was approved in 2006 in the U.S. for the treatment of advanced RCC.
Upcoming Events
-
21Oct